Drug Profile
Dronabinol - Benuvia Therapeutics
Alternative Names: 9-Tetrahydrocannabinol oral solution - INSYS Therapeutics; 9-THC oral solution - INSYS Therapeutics; Dronabinol - INSYS Therapeutics; dronabinol oral solution CII - Benuvia; dronabinol oral solution CII - INSYS Therapeutics; SYNDROSLatest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator INSYS Therapeutics, Inc
- Developer Benuvia Therapeutics; INSYS Therapeutics, Inc
- Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anorexia; Chemotherapy-induced nausea and vomiting
- Preclinical Alzheimer's disease
Most Recent Events
- 23 Apr 2024 Discontinued - Clinical-Phase-Unknown for Anorexia (In volunteers) in USA (Inhalation), before April 2024
- 23 Apr 2024 Discontinued - Phase-I for Anorexia (In volunteers) in Canada (PO), before April 2024
- 23 Apr 2024 Discontinued - Phase-I for Chemotherapy-induced nausea and vomiting (In volunteers) in Canada (PO), before April 2024